DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the appointment of Oppenheimer & Co. Inc. to serve as its strategic advisor. In this capacity, the firm will work on behalf of DelMar to manage the exploration and evaluation of a wide range of strategic opportunities with the goal of facilitating shareholder value generation.
“We believe that seeking a strategic transaction gives us the best opportunity to maximize shareholder value,” said Robert E. Hoffman, Chairman of the Board of Directors. “In addition, we continue to be dedicated to executing our ongoing Phase 2 trials for MGMT-unmethylated GBM patients at MD Anderson Cancer Center in Houston, Texas, and at Sun Yat-Sen University Cancer Center in Guangzhou, China.”
While the Company is evaluating strategic opportunities, there can be no assurance that this strategic review will result in a transaction.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.